NASDAQ:CLYM
Climb Bio, Inc.
Climb Bio, Inc. reported net income of −$59.9M in fiscal 2025. Free cash flow was −$54.5M, and the diluted share count rose 40.8%.Summary generated from Climb Bio, Inc.'s SEC filings. Latest annual report filed Mar 5, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−32.1%
Debt / equityn/a
Free cash flow−$54.5M
FCF marginn/a
Share count change+40.8%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | n/a | n/a | n/a |
| Operating income | −36 | −45 | −40 | −82 | −68 |
| Net income | −47 | −45 | −35 | −74 | −60 |
| Free cash flow | n/a | n/a | −21 | −16 | −55 |
Recent filings
- 4Insider transaction report
Sep 30, 2026 - 4Insider transaction report
Sep 17, 2026 - 8-KRegulation FD disclosure
Sep 3, 2026 - 8-KOther events
Aug 14, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 6, 2026 - 8-KResults of operations and financial condition
Aug 6, 2026 - 8-KDirector or officer change
Jul 1, 2026 - 8-KEntry into a material agreement
Jun 12, 2026